
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28683133</article-id><article-id pub-id-type="pmc">5500370</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0180726</article-id><article-id pub-id-type="publisher-id">PONE-D-17-02662</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>Antibody-Producing Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Blood Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Cell Biology</subject><subj-group><subject>Cellular Types</subject><subj-group><subject>Animal Cells</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune Cells</subject><subj-group><subject>White Blood Cells</subject><subj-group><subject>B Cells</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Anatomy</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Body Fluids</subject><subj-group><subject>Blood</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Processes</subject><subj-group><subject>Secretion</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Physiological Processes</subject><subj-group><subject>Secretion</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject><subj-group><subject>Ankylosing Spondylitis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject><subj-group><subject>Ankylosing Spondylitis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Clinical Immunology</subject><subj-group><subject>Autoimmune Diseases</subject><subj-group><subject>Ankylosing Spondylitis</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Spectrum Analysis Techniques</subject><subj-group><subject>Spectrophotometry</subject><subj-group><subject>Cytophotometry</subject><subj-group><subject>Flow Cytometry</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Gastroenterology and Hepatology</subject><subj-group><subject>Inflammatory Bowel Disease</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Research and Analysis Methods</subject><subj-group><subject>Immunologic Techniques</subject><subj-group><subject>Immunoassays</subject><subj-group><subject>Enzyme-Linked Immunoassays</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Physiology</subject><subj-group><subject>Immune Physiology</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Innate Immune System</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Developmental Biology</subject><subj-group><subject>Molecular Development</subject><subj-group><subject>Cytokines</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Increased frequency of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells with regulatory capacity in patients with Ankylosing spondylitis (AS) na&#x000ef;ve for biological agents</article-title><alt-title alt-title-type="running-head">Regulatory CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in AS</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Bautista-Caro</surname><given-names>Mar&#x000ed;a-Bel&#x000e9;n</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>de Miguel</surname><given-names>Eugenio</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Peiteado</surname><given-names>Diana</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Plasencia-Rodr&#x000ed;guez</surname><given-names>Chamaida</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Villalba</surname><given-names>Alejandro</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Monjo-Henry</surname><given-names>Irene</given-names></name><role content-type="http://credit.casrai.org/">Data curation</role><role content-type="http://credit.casrai.org/">Investigation</role><role content-type="http://credit.casrai.org/">Resources</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Puig-Kr&#x000f6;ger</surname><given-names>Amaya</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>S&#x000e1;nchez-Mateos</surname><given-names>Paloma</given-names></name><role content-type="http://credit.casrai.org/">Resources</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff002"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Mart&#x000ed;n-Mola</surname><given-names>Emilio</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref></contrib><contrib contrib-type="author"><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2334-4733</contrib-id><name><surname>Miranda-Car&#x000fa;s</surname><given-names>Mar&#x000ed;a-Eugenia</given-names></name><role content-type="http://credit.casrai.org/">Conceptualization</role><role content-type="http://credit.casrai.org/">Formal analysis</role><role content-type="http://credit.casrai.org/">Funding acquisition</role><role content-type="http://credit.casrai.org/">Methodology</role><role content-type="http://credit.casrai.org/">Project administration</role><role content-type="http://credit.casrai.org/">Supervision</role><role content-type="http://credit.casrai.org/">Validation</role><role content-type="http://credit.casrai.org/">Visualization</role><role content-type="http://credit.casrai.org/">Writing &#x02013; original draft</role><role content-type="http://credit.casrai.org/">Writing &#x02013; review &#x00026; editing</role><xref ref-type="aff" rid="aff001"><sup>1</sup></xref><xref ref-type="corresp" rid="cor001">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label><addr-line>Department of Rheumatology, Hospital Universitario La Paz-IdiPAZ, Madrid, Spain</addr-line></aff><aff id="aff002"><label>2</label><addr-line>Laboratorio de Inmuno-Oncolog&#x000ed;a, Hospital General Universitario Gregorio Mara&#x000f1;&#x000f3;n, Madrid, Spain</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Rieux-Laucat</surname><given-names>Frederic</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1"><addr-line>IMAGINE, FRANCE</addr-line></aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>None of the authors have any conflict of interest related to the work reported in the manuscript. This work was supported in part by an unrestricted research grant from Roche Pharmaceuticals (<ext-link ext-link-type="uri" xlink:href="http://www.roche.com">www.roche.com</ext-link>). This does not alter our adherence to PLOS ONE policies on sharing data and materials.</p></fn><corresp id="cor001">* E-mail: <email>mariaeugenia.miranda@salud.madrid.org</email></corresp></author-notes><pub-date pub-type="epub"><day>6</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="collection"><year>2017</year></pub-date><volume>12</volume><issue>7</issue><elocation-id>e0180726</elocation-id><history><date date-type="received"><day>20</day><month>1</month><year>2017</year></date><date date-type="accepted"><day>20</day><month>6</month><year>2017</year></date></history><permissions><copyright-statement>&#x000a9; 2017 Bautista-Caro et al</copyright-statement><copyright-year>2017</copyright-year><copyright-holder>Bautista-Caro et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0180726.pdf"/><abstract><p>Our objective was to study the frequency of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells (Breg) in AS patients. To this end, peripheral blood was drawn from AS patients na&#x000ef;ve for TNF blockers (AS/nb) (n = 42) and healthy controls (HC) (n = 42). Six patients donated blood for a second time, 6 months after initiating treatment with anti-TNF&#x003b1; drugs. After isolation by Ficoll-Hypaque, PBMCs were stained with antibodies to CD3, CD4, CD19, CD24, and CD38, and examined by cytometry. For functional studies, total CD19+ B cells were isolated from PBMCs of 3 HC by magnetical sorting. Breg-depleted CD19+ B cells were obtained after CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells were removed from total CD19+ cells by cytometry. Total CD19+ B cells or Breg-depleted CD19+ B cells were established in culture and stimulated through their BCR. Secretion of IFN&#x003b3; was determined by ELISA in culture supernatants. When compared with HC, AS/nb patients demonstrated a significantly increased frequency of Breg cells, which was independent of disease activity. Anti-TNF&#x003b1; drugs induced a significant reduction of circulating Breg numbers, which were no longer elevated after six months of treatment. Functional in vitro studies showed that the secretion of IFN&#x003b3; was significantly higher in Breg-depleted as compared with total CD19+ B cells, indicating that Breg can downmodulate B cell pro-inflammatory cytokine secretion. In summary, an increased frequency of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells is observed in AS/nb patients, that is not related with disease activity; anti-TNF&#x003b1; drugs are able to downmodulate circulating Breg numbers in AS.</p></abstract><funding-group><award-group id="award001"><funding-source><institution>Instituto de Salud Carlos III (ES)</institution></funding-source><award-id>FIS PI-16/01189</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2334-4733</contrib-id><name><surname>Miranda-Car&#x000fa;s</surname><given-names>Mar&#x000ed;a-Eugenia</given-names></name></principal-award-recipient></award-group><award-group id="award002"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>RD12/0009/0012</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2334-4733</contrib-id><name><surname>Miranda-Car&#x000fa;s</surname><given-names>Mar&#x000ed;a-Eugenia</given-names></name></principal-award-recipient></award-group><award-group id="award003"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100004587</institution-id><institution>Instituto de Salud Carlos III</institution></institution-wrap></funding-source><award-id>RD16/0012/0012</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2334-4733</contrib-id><name><surname>Miranda-Car&#x000fa;s</surname><given-names>Mar&#x000ed;a-Eugenia</given-names></name></principal-award-recipient></award-group><award-group id="award004"><funding-source><institution-wrap><institution-id institution-id-type="funder-id">http://dx.doi.org/10.13039/501100008433</institution-id><institution>Consejer&#x000ed;a de Educaci&#x000f3;n, Juventud y Deporte, Comunidad de Madrid</institution></institution-wrap></funding-source><award-id>S2010/BMD-2350</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2334-4733</contrib-id><name><surname>Miranda-Car&#x000fa;s</surname><given-names>Mar&#x000ed;a-Eugenia</given-names></name></principal-award-recipient></award-group><award-group id="award005"><funding-source><institution>Roche Pharmaceuticals</institution></funding-source><award-id>Unrestricted research</award-id><principal-award-recipient><contrib-id authenticated="true" contrib-id-type="orcid">http://orcid.org/0000-0002-2334-4733</contrib-id><name><surname>Miranda-Car&#x000fa;s</surname><given-names>Mar&#x000ed;a-Eugenia</given-names></name></principal-award-recipient></award-group><funding-statement>This work was supported by Ministerio de Econom&#x000ed;a y Competitividad/Instituto de Salud Carlos III (MINECO/ISCIII) grant numbers FIS PI-16/01189, RD12/0009/0012 and RD16/0012/0012 (RIER, RETICS Program) (<ext-link ext-link-type="uri" xlink:href="http://www.idi.mineco.gob.es/portal/site/MICINN">http://www.idi.mineco.gob.es/portal/site/MICINN</ext-link>, <ext-link ext-link-type="uri" xlink:href="http://www.isciii.es">http://www.isciii.es</ext-link>), by COnsejer&#x000ed;a de Educaci&#x000f3;n de la Comunidad de Madrid/Fondo Europeo de Desarrollo Regional RAPHYME, grant number S2010/BMD-2350 (<ext-link ext-link-type="uri" xlink:href="http://www.madrimasd.org">www.madrimasd.org</ext-link>) and by an unrestricted research grant from Roche Pharmaceuticals (<ext-link ext-link-type="uri" xlink:href="http://www.roche.com">www.roche.com</ext-link>). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><fig-count count="4"/><table-count count="1"/><page-count count="11"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>All relevant data are within the paper and supplementary tables.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>All relevant data are within the paper and supplementary tables.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>The pathogenesis of Ankylosing spondylitis (AS), the prototype form of Spondyloarthritis (SpA), is not well understood, and evidence indicating a role for either autoinflammatory or autoimmune mechanisms has been described [<xref rid="pone.0180726.ref001" ref-type="bibr">1</xref>]. An interesting report by Cantaert et al [<xref rid="pone.0180726.ref002" ref-type="bibr">2</xref>] has shown an increased number of IL-10 producing CD19+CD5+ B lymphocytes in SpA.</p><p>B cells are not merely a source of antibodies [<xref rid="pone.0180726.ref003" ref-type="bibr">3</xref>]; they also act as very efficient antigen presenting cells and as cytokine producers [<xref rid="pone.0180726.ref003" ref-type="bibr">3</xref>]. In addition regulatory B cells, a subspecialized B cell subset, contribute to the maintenance of peripheral tolerance by downmodulating T and B cell function [<xref rid="pone.0180726.ref004" ref-type="bibr">4</xref>,<xref rid="pone.0180726.ref005" ref-type="bibr">5</xref>]. Phenotypical characterization of Bregs in mice or humans is not straightforward, and different definitions of Bregs have been proposed based on distinct cell surface markers [<xref rid="pone.0180726.ref006" ref-type="bibr">6</xref>]; however, Bregs have not been demonstrated to constitute a unique cell lineage [<xref rid="pone.0180726.ref006" ref-type="bibr">6</xref>]. Therefore, IL-10 production together with functional inhibition of T or B cell responses remain the gold standard for Breg definition [<xref rid="pone.0180726.ref006" ref-type="bibr">6</xref>].</p><p>In human peripheral blood, immature CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells contain a high proportion of IL-10 producing cells [<xref rid="pone.0180726.ref007" ref-type="bibr">7</xref>,<xref rid="pone.0180726.ref008" ref-type="bibr">8</xref>] and functionally behave as suppressors of Th1 responses and Th17 differentiation [<xref rid="pone.0180726.ref009" ref-type="bibr">9</xref>]. In addition, CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells are able to induce Treg and Tr1 phenotype from CD4+ T cells [<xref rid="pone.0180726.ref009" ref-type="bibr">9</xref>].</p><p>Patients with autoimmune conditions such as systemic lupus erythematosus (SLE) [<xref rid="pone.0180726.ref007" ref-type="bibr">7</xref>], RA [<xref rid="pone.0180726.ref009" ref-type="bibr">9</xref>], primary Sj&#x000f6;gren&#x02032;s syndrome [<xref rid="pone.0180726.ref010" ref-type="bibr">10</xref>], ANCA-associated vasculitis [<xref rid="pone.0180726.ref011" ref-type="bibr">11</xref>], and Systemic Sclerosis [<xref rid="pone.0180726.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0180726.ref013" ref-type="bibr">13</xref>], have been shown to demonstrate altered numbers and/or function of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells. In addition, whereas Cantaert et al described an increased number of circulating CD19+CD5+ B cells with a regulatory phenotype in SpA [<xref rid="pone.0180726.ref002" ref-type="bibr">2</xref>], Chen et al reported normal numbers of CD19+CD24+CD38+ B cells with decreased IL-10 production in AS patients [<xref rid="pone.0180726.ref014" ref-type="bibr">14</xref>]. To our knowledge, these are the two only published reports on the numbers of circulating B cells with regulatory properties in SpA. Therefore, our objective was to investigate on the frequency of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in AS and test the regulatory capacity of this B cell subset.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Patients and methods</title><sec id="sec003"><title>Ethics statement</title><p>The study was approved by the Hospital La Paz&#x02014;IdiPAZ Ethics Committee (protocol number HULP PI-883), and all subjects provided written informed consent according to the Declaration of Helsinki.</p></sec><sec id="sec004"><title>Patients</title><p>Peripheral blood was obtained from 42 AS patients who had never received TNF blockers (AS/nb) (<xref ref-type="table" rid="pone.0180726.t001">Table 1</xref> and <xref ref-type="supplementary-material" rid="pone.0180726.s001">S1 Table</xref>) and from 42 age and gender-matched healthy controls (HC) (<xref ref-type="supplementary-material" rid="pone.0180726.s002">S2 Table</xref>). All subjects were studied between the years 2014 and 2016. Patients were recruited among those attending the outpatient Rheumatology Clinic at Hospital Universitario La Paz (Madrid, Spain). Inclusion criteria for patients were age greater than 18 years and AS diagnosis according to the 1984 modified New York criteria [<xref rid="pone.0180726.ref015" ref-type="bibr">15</xref>], exclusion criteria were a history of previous treatment with biological agents and infection with HBV, HCV or HIV. Healthy controls were recruited among hospital and laboratory workers. Inclusion criteria for controls were age greater than 18 years; exclusion criteria for controls were current or chronic medication intake, the presence of any known disease condition or infection with HBV, HCV or HIV. Forty-seven patients were approached and 42 accepted to participate; fifty controls were approached and 42 accepted to participate. There were no dropouts. Among patients, 28 were taking non-steroidal anti-inflammatory drugs (NSAIDs), 7 were receiving sulfasalazine (SSZ); 3 methotrexate (MTX) and 7 of them did not take any medication regularly. 31 patients had a pure axial disease (13 female, 18 male) and 11 patients (4 female, 7 male) had a combination of axial and peripheral manifestations (<xref ref-type="table" rid="pone.0180726.t001">Table 1</xref> and <xref ref-type="supplementary-material" rid="pone.0180726.s001">S1 Table</xref>). All subjects were of Western European descent.</p><table-wrap id="pone.0180726.t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0180726.t001</object-id><label>Table 1</label><caption><title>Clinical characteristics of AS/nb patients.</title></caption><alternatives><graphic id="pone.0180726.t001g" xlink:href="pone.0180726.t001"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="justify" rowspan="1" colspan="1"/><th align="justify" rowspan="1" colspan="1">AS/nb (n = 42)</th></tr></thead><tbody><tr><td align="justify" rowspan="1" colspan="1">Age (years); median (IQR)</td><td align="justify" rowspan="1" colspan="1">52 (39.5&#x02013;62)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Male; n&#x000b0; (%)</td><td align="justify" rowspan="1" colspan="1">25 (59.5)</td></tr><tr><td align="justify" rowspan="1" colspan="1">HLA-B27+; n&#x000b0; (%)</td><td align="justify" rowspan="1" colspan="1">35 (85.4)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Duration of symptoms (yrs); median (IQR)</td><td align="justify" rowspan="1" colspan="1">20.5 (10.0&#x02013;34.5)</td></tr><tr><td align="justify" rowspan="1" colspan="1">Time since diagnosis (yrs); median (IQR)</td><td align="justify" rowspan="1" colspan="1">10 (4&#x02013;19)</td></tr><tr><td align="justify" rowspan="1" colspan="1">BASDAI; median (IQR)</td><td align="justify" rowspan="1" colspan="1">4.6 (3.05&#x02013;6.80)</td></tr><tr><td align="justify" rowspan="1" colspan="1">BASFI; median (IQR)</td><td align="justify" rowspan="1" colspan="1">2.9 (0.85&#x02013;5.70)</td></tr><tr><td align="justify" rowspan="1" colspan="1">ASDAS-ESR; median (IQR)</td><td align="justify" rowspan="1" colspan="1">2.27 (1.92&#x02013;3.38)</td></tr><tr><td align="justify" rowspan="1" colspan="1">ASDAS-CRP; median (IQR)</td><td align="justify" rowspan="1" colspan="1">2.80 (2.04&#x02013;3.70)</td></tr><tr><td align="justify" rowspan="1" colspan="1">CRP; median (IQR)</td><td align="justify" rowspan="1" colspan="1">7.92 (3.25&#x02013;12.45)</td></tr><tr><td align="justify" rowspan="1" colspan="1">ESR; median (IQR)</td><td align="justify" rowspan="1" colspan="1">9 (5.5&#x02013;14.0)</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p>AS/nb: AS patients na&#x000ef;ve for TNF blockers</p></fn></table-wrap-foot></table-wrap><p>Six AS/nb patients intitiated treatment with anti-TNF&#x003b1; antibodies (2 infliximab, 2 golimumab, 1 adalimumab, 1 certolizumab). Four of them were male, and 5 were HLA B27+; age was 41.0 (33.0&#x02013;59.5) years (median, IQR), duration of symptoms was 9.0 (2.0&#x02013;19.5) years, time since diagnosis 6.0 (0.5&#x02013;12.0) years, and ASDAS-CRP 3.87 (2.38&#x02013;4.48). These patients donated blood on two occasions: right before the first dose of biological agent was administered, and 6 months thereafter. For each patient, one healthy subject served as control on both the first and second occasion.</p></sec><sec id="sec005"><title>Isolation of B cells from human peripheral blood</title><p>Peripheral blood mononuclear cells (PBMCs) were separated immediately after blood sample collection, by Ficoll-Hypaque (GE Healthcare Biosciences AB, Uppsala, Sweden) density gradient centrifugation. Highly purified B cells were prepared from PBMCs by exhaustive immunomagnetic negative selection in an Automacs (Miltenyi Biotec, Bergisch Gladbach, Germany) using a B cell negative isolation kit (Miltenyi Biotec), containing biotinylated antibodies against CD2, CD14, CD16, CD36, CD43, and CD235a (glycophorin A). The purity of the isolated B cells as assessed by flow cytometry using a fluorochrome-conjugated anti-CD19 mAb was greater than 98%. Subsequently, Breg-depleted CD19+ B cells were obtained after removing CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells from total CD19+ B cells by cytometry in a FacsVantage SE sorter (Beckton Dickinson). The purity of Breg-depleted B cells was &#x0003e;98%.</p></sec><sec id="sec006"><title>B cell cultures</title><p>To assess the regulatory capacity of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells (Breg) on B cell cytokine secretion, total CD19+ B cells or Breg-depleted CD19+ B cells (1x10<sup>5</sup> cells/well) were cultured for 7 days in U-bottom 96-well plates containing RPMI 1640 medium (Lonza, Alendale, NJ, USA) with 10% FCS, 2 mM L-glutamine, 50 U/ml penicillin, 50 mg/ml streptomycin and 50 mM 2-mercaptoethanol, in the presence of 10&#x003bc;g/ml F(ab')2 Goat Anti-Human IgM+IgG Functional Grade Purified (eBioscience). Secretion of IFN&#x003b3; was determined by ELISA in culture supernatants at different time points.</p></sec><sec id="sec007"><title>Cell surface staining and flow cytometry</title><p>The frequency and phenotype of Breg cells present in the peripheral blood of AS patients and HC was assessed by flow cytometry after staining freshly isolated PBMCs with antibodies directed to surface phenotypical markers. Fluorochrome-conjugated mAbs from BD Pharmingen (San Diego, CA, USA) were used to examine the expression of CD3, CD4, CD19, CD24 and CD38 in a FACSCalibur flow cytometer with CellQuest software (BD Biosciences).</p></sec><sec id="sec008"><title>ELISAs</title><p>Cell-free culture supernatants were collected and stored at -80&#x000b0;C. The concentration of IFN&#x003b3; was determined by ELISA using a kit from BD Biosciences and following the manufacturer&#x02032;s instructions. Serum calprotectin was determined by ELISA with a kit from Hycult Biotech (Ulden, The Netherlands).</p></sec><sec id="sec009"><title>Statistical analysis</title><p>Comparison between groups was by Mann-Whitney test. Paired samples were compared using a Wilcoxon matched pairs signed rank sum test. Correlations were analyzed using Spearman&#x02019;s rank correlation coefficients. P values less than 0.05 were considered significant. All analyses were performed using Prism version 5.0 software (GraphPad Software).</p></sec></sec><sec sec-type="results" id="sec010"><title>Results</title><sec id="sec011"><title>Patients with AS/nb demonstrate increased numbers of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells</title><p>We first sought to examine the expression of Breg phenotypical surface markers on CD19+ B cells present in the peripheral blood of AS/nb patients. The absolute numbers of circulating total CD19+ B cells were not different in AS/nb as compared with healthy control subjects: median (IQR), 151.7 (105.8&#x02013;216.7) in AS/nb vs 131.6 (90.71&#x02013;165.8) x10<sup>3</sup>/ml in HC, p&#x0003e;0.1. In contrast, both the frequency and the absolute number of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells, were significantly increased in AS/nb patients na&#x000ef;ve for TNF blockers, as compared with HC: median (IQR) 4.46% (3.08&#x02013;6.20%) or 6.69 x10<sup>3</sup>/ml (3.98&#x02013;11.24 x10<sup>3</sup>/ml) in AS/nb vs 3.28% (2.36&#x02013;4.27%) or 4.17 x10<sup>3</sup>/ml (3.11&#x02013;5.58 x10<sup>3</sup>/ml) in HC, p&#x0003c;0.01 (<xref ref-type="fig" rid="pone.0180726.g001">Fig 1</xref>).</p><fig id="pone.0180726.g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0180726.g001</object-id><label>Fig 1</label><caption><title>Numbers of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in AS patients na&#x000ef;ve for TNF blockers (AS/nb).</title><p>PBMCs isolated from the peripheral blood of AS/nb patients (n = 42) and from age and gender-matched healthy controls (HC) (n = 42) were stained with fluorochrome-labeled antibodies against cell surface markers and examined by flow cytometry. AS/nb patients showed an increased proportion and absolute numbers of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells. A. Representative dot plots demonstrate CD24 and CD38 expression in cells gated for CD19. B, C. Frequency (B) and absolute numbers (C) of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in HC and AS/nb patients. Bars represent the median and interquartile range. *p&#x0003c;0.01.</p></caption><graphic xlink:href="pone.0180726.g001"/></fig></sec><sec id="sec012"><title>Relation of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cell frequency with disease activity</title><p>The frequency of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells did not correlate significantly with BASDAI, CRP, ESR, ASDAS-CRP or ASDAS-ESR (<xref ref-type="fig" rid="pone.0180726.g002">Fig 2A</xref>). Patients with AS/nb demonstrated significantly elevated levels of serum calprotectin as compared with controls (p&#x0003c;0.001) (<xref ref-type="fig" rid="pone.0180726.g002">Fig 2B</xref>). Serum calprotectin correlated significantly with CRP and ASDAS-CRP but not with the frequency of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells (<xref ref-type="fig" rid="pone.0180726.g002">Fig 2C</xref>).</p><fig id="pone.0180726.g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0180726.g002</object-id><label>Fig 2</label><caption><title>The frequency of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in AS/nb patients is not related with disease activity scores and/or inflammatory serological markers.</title><p>A. The frequency of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells is not related with BASDAI, CRP, ESR, ASDAS-CRP or ASDAS-ESR. B. AS/nb patients demonstrate increased levels of calprotectin as compared with HC. *p &#x0003c;0.001 C. Serum calprotectin concentrations were significantly correlated with CRP and ASDAS-CRP but not with the frequency of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells.</p></caption><graphic xlink:href="pone.0180726.g002"/></fig></sec><sec id="sec013"><title>Treatment with anti-TNF agents is associated with a significant reduction of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cell numbers in AS patients</title><p>We then sought to determine whether treatment with anti-TNF&#x003b1; agents is able to modify the altered numbers of Breg cells observed in the peripheral blood of AS/nb patients. Six AS patients previously na&#x000ef;ve for TNF blockers and who had an incomplete response to NSAIDs, donated blood right before the initiation of an anti-TNF&#x003b1; monoclonal antibody, and six months thereafter. Blood was also obtained from six healthy subjects, who acted as controls for each patient at both the first and 6-month examination. When compared with basal data, at the six month evaluation all 6 AS patients demonstrated a marked reduction in the frequency of circulating Breg cells (p&#x0003c;0.05), whereas experimental variation observed in healthy controls was minimal (p&#x0003e;0.1) (<xref ref-type="fig" rid="pone.0180726.g003">Fig 3A</xref>). At the same time, decreased values of CRP (p&#x0003c;0.05), calprotectin (p&#x0003c;0.05) and ASDAS-CRP (p&#x0003c;0.05) were observed in all patients (<xref ref-type="fig" rid="pone.0180726.g003">Fig 3B</xref>). Four of these patients experienced a major clinical improvement as determined by a reduction of the ASDAS-CRP index greater than 2.0 units [<xref rid="pone.0180726.ref016" ref-type="bibr">16</xref>].</p><fig id="pone.0180726.g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0180726.g003</object-id><label>Fig 3</label><caption><title>Treatment with anti-TNF agents is associated with a significant reduction of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cell numbers in AS patients.</title><p>A. Frequency of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in six AS patients before and six months after initiating treatment with anti-TNF&#x003b1; agents, and in their 6 age and gender-matched healthy controls at the basal and 6 month study. (*p&#x0003c;0.05) B. CRP, calprotectin and ASDAS-CRP values in these 6 AS/nb patients before and six months after initiating treatment with anti-TNF&#x003b1;. (*p&#x0003c;0.05)</p></caption><graphic xlink:href="pone.0180726.g003"/></fig></sec><sec id="sec014"><title>Negative regulatory capacity of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells</title><p>Total CD19+ or Breg-depleted CD19+ B cells (B cells depleted of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> cells) were isolated from the peripheral blood of three healthy controls (HC), established in culture and stimulated with anti-IgM+IgG MoAbs. Secretion of IFN&#x003b3; was determined in culture supernatants by sandwich ELISA at 2, 5 or 7 days. When compared with total CD19+ B cells, Breg-depleted CD19+ B cells secreted an increased amount of IFN&#x003b3; at all tested time points (2, 5 and 7 days) (<xref ref-type="fig" rid="pone.0180726.g004">Fig 4</xref>).</p><fig id="pone.0180726.g004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0180726.g004</object-id><label>Fig 4</label><caption><title>Suppressive capacity of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in healthy subjects.</title><p>Total CD19+ or B cells depleted of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> cells (Breg-depleted CD19+ B cells), isolated from the peripheral blood of three healthy controls (HC), were established in culture, and stimulated with anti-IgM+IgG. Secretion of IFN&#x003b3; was determined in culture supernatants by sandwich ELISA at 2, 5 or 7 days. Bar graphs represent the mean and SEM for IFN&#x003b3; concentrations of 3 independent experiments.</p></caption><graphic xlink:href="pone.0180726.g004"/></fig></sec></sec><sec sec-type="conclusions" id="sec015"><title>Discussion</title><p>We have herein described an increased frequency and absolute number of CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells in AS patients na&#x000ef;ve for biological agents, that is not related with disease activity measures. These results parallel data published by Cantaert el al, who reported on elevated numbers of CD19+CD5+ B cells with a regulatory phenotype in SpA, independent of disease activity [<xref rid="pone.0180726.ref002" ref-type="bibr">2</xref>]. Assessment of clinical activity in SpA is difficult due to the lack of a universally accepted &#x02018;gold standard&#x02019; [<xref rid="pone.0180726.ref016" ref-type="bibr">16</xref>], and because some of the currently used indices measure only one aspect of the disease or are mostly patient or physician oriented. Therefore we were interested in ascertaining whether the lack of correlation of Breg cell numbers with ASDAS-CRP was relevant. Serum calprotectin has recently emerged as a good biomarker for disease activity in SpA [<xref rid="pone.0180726.ref017" ref-type="bibr">17</xref>,<xref rid="pone.0180726.ref018" ref-type="bibr">18</xref>] and we observed that serum calprotectin concentrations were significantly correlated with CRP and ASDAS-CRP but not with the percentage of circulating Breg cells, thereby confirming that Breg cell numbers do not vary with disease activity in AS.</p><p>The gold standard for Breg cell definition remains the ascertainment of their regulatory capacity [<xref rid="pone.0180726.ref006" ref-type="bibr">6</xref>]. We observed that Breg-depleted CD19+ B cells secreted increased amounts of IFN&#x003b3; as compared with total CD19+ B cells, indicating that Breg downregulate pro-inflammatory B cell cytokine secretion. Breg cells have been described to negatively modulate T cell responses [<xref rid="pone.0180726.ref004" ref-type="bibr">4</xref>&#x02013;<xref rid="pone.0180726.ref007" ref-type="bibr">7</xref>] and downmodulate CD86 expression on B cells [<xref rid="pone.0180726.ref008" ref-type="bibr">8</xref>]. Our results indicate an autoregulatory action of Breg cells on B effector cell cytokine secretion, and this is an aspect of Breg function which had not been described previously.</p><p>The contribution of adaptive immunity to the pathogenesis of AS has not been established [<xref rid="pone.0180726.ref001" ref-type="bibr">1</xref>] and the possible role of increased Breg cells in the peripheral blood of AS patients does not have a straightforward explanation. One likely possibilty is that augmented Breg numbers are a reflection of chronic immune system stimulation at the gut. In fact, AS patients demonstrate an altered gut microbiome [<xref rid="pone.0180726.ref019" ref-type="bibr">19</xref>], which may be influenced by HLA-27 [<xref rid="pone.0180726.ref020" ref-type="bibr">20</xref>]. In addition, an increased intestinal permeability has been described not only in patients with AS but also in their healthy relatives [<xref rid="pone.0180726.ref021" ref-type="bibr">21</xref>]. Furthermore, subclinical gut inflammation can be observed in up to 65&#x02013;70% of AS patients [<xref rid="pone.0180726.ref022" ref-type="bibr">22</xref>]. It is associated with an increased amount of local lymphoid follicles [<xref rid="pone.0180726.ref023" ref-type="bibr">23</xref>] and with a pro-angiogenic intestinal phenotype [<xref rid="pone.0180726.ref024" ref-type="bibr">24</xref>], that can facilitate an enhanced trafficking of immune cells.</p><p>Of note, the gut microbiota has been shown to be involved in the development of several autoimmune / autoinflammatory conditions including arthritis [<xref rid="pone.0180726.ref025" ref-type="bibr">25</xref>&#x02013;<xref rid="pone.0180726.ref027" ref-type="bibr">27</xref>]. At the same time, it plays an important role in the generation of Breg cells thereby providing a negative feedback for inflammation [<xref rid="pone.0180726.ref026" ref-type="bibr">26</xref>,<xref rid="pone.0180726.ref027" ref-type="bibr">27</xref>]. Interestingly, the gut microflora is able to induce Breg differentiation not only at the intestinal lymphoid tissue, but also at the spleen [<xref rid="pone.0180726.ref027" ref-type="bibr">27</xref>]; this may indicate the existence of B cell trafficking from the gut to other organs [<xref rid="pone.0180726.ref027" ref-type="bibr">27</xref>], and/or the effect of specific gut microbiota metabolites signaling at distant sites [<xref rid="pone.0180726.ref028" ref-type="bibr">28</xref>].</p><p>In this context, there is evidence for an increased frequency of circulating CD19+/ CD38<sup>hi</sup>/ CD24<sup>hi</sup>/IL-10+ B cells in active IBD patients as compared with inactive disease or healthy controls [<xref rid="pone.0180726.ref029" ref-type="bibr">29</xref>], suggesting that Breg cells may act downregulating gut inflammation in patients with disease activity [<xref rid="pone.0180726.ref029" ref-type="bibr">29</xref>].</p><p>Importantly, whereas Breg numbers were significantly increased in our AS patients na&#x000ef;ve for biological agents, independently of disease activity parameters, we observed that treatment with anti-TNF&#x003b1; was associated with a reduction of circulating Breg cell numbers. We can speculate that this is reflecting a modification of microbiome composition, gut barrier integritiy, and/or an improvement of subclinical gut mucosal inflammation that is only achieved by this treatment, given the leading role of TNF&#x003b1; in gut homeostasis and in the pathogenesis of inflammatory bowel disease [<xref rid="pone.0180726.ref030" ref-type="bibr">30</xref>&#x02013;<xref rid="pone.0180726.ref034" ref-type="bibr">34</xref>]. Also, a potent downregulation of inflammatory mediators by anti-TNF&#x003b1; treatment may lead to reduced Breg numbers, given the dependency of Breg cell generation on the local inflammatory milieu [<xref rid="pone.0180726.ref006" ref-type="bibr">6</xref>].</p><p>This study is limited by the high amount of blood required for functional assays, which hampered the recruitement of patients for this purpose, and by the absence of clinical /laboratory data on subclinical gut inflammation or microbiota composition of our patients.</p></sec><sec sec-type="conclusions" id="sec016"><title>Conclusion</title><p>In summary, we have described increased numbers of circulating CD19+CD24<sup>hi</sup>CD38<sup>hi</sup> B cells (Breg) in AS/nb patients, that are not related with disease activity. Treatment with anti-TNF&#x003b1; drugs is able to downmodulate circulating Breg cell numbers in AS.</p></sec><sec sec-type="supplementary-material" id="sec017"><title>Supporting information</title><supplementary-material content-type="local-data" id="pone.0180726.s001"><label>S1 Table</label><caption><title>Clinical data of AS/nb patients.</title><p>(DOCX)</p></caption><media xlink:href="pone.0180726.s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material content-type="local-data" id="pone.0180726.s002"><label>S2 Table</label><caption><title>Age and gender of healthy controls.</title><p>(DOCX)</p></caption><media xlink:href="pone.0180726.s002.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ref-list><title>References</title><ref id="pone.0180726.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Ambarus</surname><given-names>C</given-names></name>, <name><surname>Yeremenko</surname><given-names>N</given-names></name>, <name><surname>Tak</surname><given-names>PP</given-names></name>, <name><surname>Baeten</surname><given-names>D</given-names></name>. <article-title>Pathogenesis of spondyloarthritis: autoimmune or autoinflammatory?</article-title>
<source>Curr Opin Rheumatol</source>. <year>2012</year>;<volume>24</volume>:<fpage>351</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/BOR.0b013e3283534df4">10.1097/BOR.0b013e3283534df4</ext-link></comment>
<pub-id pub-id-type="pmid">22488076</pub-id></mixed-citation></ref><ref id="pone.0180726.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Cantaert</surname><given-names>T</given-names></name>, <name><surname>Doorenspleet</surname><given-names>ME</given-names></name>, <name><surname>Francosalinas</surname><given-names>G</given-names></name>, <name><surname>Paramarta</surname><given-names>JE</given-names></name>, <name><surname>Klarenbeek</surname><given-names>PL</given-names></name>, <name><surname>Tiersma</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Increased numbers of CD5+ B lymphocytes with a regulatory phenotype in spondylarthritis</article-title>. <source>Arthritis Rheum</source>. <year>2012</year>;<volume>64</volume>:<fpage>1859</fpage>&#x02013;<lpage>68</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/art.34364">10.1002/art.34364</ext-link></comment>
<pub-id pub-id-type="pmid">22231660</pub-id></mixed-citation></ref><ref id="pone.0180726.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Silverman</surname><given-names>GJ</given-names></name>, <name><surname>Carson</surname><given-names>DA</given-names></name>. <article-title>Roles of B cells in rheumatoid arthritis</article-title>. <source>Arthritis Res Ther</source>. <year>2003</year>;<volume>5</volume>
<issue>Suppl 4</issue>:<fpage>S1</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="pone.0180726.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Lund</surname><given-names>FE</given-names></name>, <name><surname>Randall</surname><given-names>TD</given-names></name>. <article-title>Effector and regulatory B cells: modulators of CD4+ T cell immunity</article-title>. <source>Nat Rev Immunol</source>. <year>2010</year>;<volume>10</volume>:<fpage>236</fpage>&#x02013;<lpage>47</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nri2729">10.1038/nri2729</ext-link></comment>
<pub-id pub-id-type="pmid">20224569</pub-id></mixed-citation></ref><ref id="pone.0180726.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Rosser</surname><given-names>EC</given-names></name>, <name><surname>Blair</surname><given-names>PA</given-names></name>, <name><surname>Mauri</surname><given-names>C</given-names></name>. <article-title>Cellular targets of regulatory B cell-mediated suppression</article-title>. <source>Mol Immunol</source>. <year>2014</year>;<volume>62</volume>:<fpage>296</fpage>&#x02013;<lpage>304</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.molimm.2014.01.014">10.1016/j.molimm.2014.01.014</ext-link></comment>
<pub-id pub-id-type="pmid">24556109</pub-id></mixed-citation></ref><ref id="pone.0180726.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Mauri</surname><given-names>C</given-names></name>, <name><surname>Menon</surname><given-names>M</given-names></name>. <article-title>The expanding family of regulatory B cells</article-title>. <source>Int Immunol</source>. <year>2015</year>;<volume>27</volume>:<fpage>479</fpage>&#x02013;<lpage>86</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1093/intimm/dxv038">10.1093/intimm/dxv038</ext-link></comment>
<pub-id pub-id-type="pmid">26071023</pub-id></mixed-citation></ref><ref id="pone.0180726.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Blair</surname><given-names>PA</given-names></name>, <name><surname>Nore&#x000f1;a</surname><given-names>LY</given-names></name>, <name><surname>Flores-Borja</surname><given-names>F</given-names></name>, <name><surname>Rawlings</surname><given-names>DJ</given-names></name>, <name><surname>Isenberg</surname><given-names>DA</given-names></name>, <name><surname>Ehrenstein</surname><given-names>MR</given-names></name>, <name><surname>Mauri</surname><given-names>C</given-names></name>. <article-title>CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients</article-title>. <source>Immunity</source>. <year>2010</year>;<volume>32</volume>:<fpage>129</fpage>&#x02013;<lpage>40</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.immuni.2009.11.009">10.1016/j.immuni.2009.11.009</ext-link></comment>
<pub-id pub-id-type="pmid">20079667</pub-id></mixed-citation></ref><ref id="pone.0180726.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Nova-Lamperti</surname><given-names>E</given-names></name>, <name><surname>Fanelli</surname><given-names>G</given-names></name>, <name><surname>Becker</surname><given-names>PD</given-names></name>, <name><surname>Chana</surname><given-names>P</given-names></name>, <name><surname>Elgueta</surname><given-names>R</given-names></name>, <name><surname>Dodd</surname><given-names>PC</given-names></name>, <etal>et al</etal>
<article-title>IL-10-produced by human transitional B-cells down-regulates CD86 expression on B-cells leading to inhibition of CD4(+)T-cell responses</article-title>. <source>Sci Rep</source>. <year>2016</year>;<volume>6</volume>:<fpage>20044</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/srep20044">10.1038/srep20044</ext-link></comment>
<pub-id pub-id-type="pmid">26795594</pub-id></mixed-citation></ref><ref id="pone.0180726.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Flores-Borja</surname><given-names>F</given-names></name>, <name><surname>Bosma</surname><given-names>A</given-names></name>, <name><surname>Ng</surname><given-names>D</given-names></name>, <name><surname>Reddy</surname><given-names>V</given-names></name>, <name><surname>Ehrenstein</surname><given-names>MR</given-names></name>, <name><surname>Isenberg</surname><given-names>DA</given-names></name>, <name><surname>Mauri</surname><given-names>C</given-names></name>. <article-title>CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation</article-title>. <source>Sci Transl Med</source>. <year>2013</year>;<volume>5</volume>:<fpage>173ra23</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1126/scitranslmed.3005407">10.1126/scitranslmed.3005407</ext-link></comment>
<pub-id pub-id-type="pmid">23427243</pub-id></mixed-citation></ref><ref id="pone.0180726.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Furuzawa-Carballeda</surname><given-names>J</given-names></name>, <name><surname>Hern&#x000e1;ndez-Molina</surname><given-names>G</given-names></name>, <name><surname>Lima</surname><given-names>G</given-names></name>, <name><surname>Rivera-Vicencio</surname><given-names>Y</given-names></name>, <name><surname>F&#x000e9;rez-Blando</surname><given-names>K</given-names></name>, <name><surname>Llorente</surname><given-names>L</given-names></name>. <article-title>Peripheral regulatory cells immunophenotyping in primary Sj&#x000f6;gren's syndrome: a cross-sectional study</article-title>. <source>Arthritis Res Ther</source>. <year>2013</year>;<volume>15</volume>:<fpage>R68</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/ar4245">10.1186/ar4245</ext-link></comment>
<pub-id pub-id-type="pmid">23800367</pub-id></mixed-citation></ref><ref id="pone.0180726.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Todd</surname><given-names>SK</given-names></name>, <name><surname>Pepper</surname><given-names>RJ</given-names></name>, <name><surname>Draibe</surname><given-names>J</given-names></name>, <name><surname>Tanna</surname><given-names>A</given-names></name>, <name><surname>Pusey</surname><given-names>CD</given-names></name>, <name><surname>Mauri</surname><given-names>C</given-names></name>, <name><surname>Salama</surname><given-names>AD</given-names></name>. <article-title>Regulatory B cells are numerically but not functionally deficient in anti-neutrophil cytoplasm antibody-associated vasculitis</article-title>. <source>Rheumatology (Oxford)</source>. <year>2014</year>;<volume>53</volume>:<fpage>1693</fpage>&#x02013;<lpage>703</lpage>.<pub-id pub-id-type="pmid">24729396</pub-id></mixed-citation></ref><ref id="pone.0180726.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Mavropoulos</surname><given-names>A</given-names></name>, <name><surname>Simopoulou</surname><given-names>T</given-names></name>, <name><surname>Varna</surname><given-names>A</given-names></name>, <name><surname>Liaskos</surname><given-names>C</given-names></name>, <name><surname>Katsiari</surname><given-names>CG</given-names></name>, <name><surname>Bogdanos</surname><given-names>DP</given-names></name>, <name><surname>Sakkas</surname><given-names>LI</given-names></name>. <article-title>Breg Cells Are Numerically Decreased and Functionally Impaired in Patients With Systemic Sclerosis</article-title>. <source>Arthritis Rheumatol</source>. <year>2016</year>;<volume>68</volume>:<fpage>494</fpage>&#x02013;<lpage>504</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/art.39437">10.1002/art.39437</ext-link></comment>
<pub-id pub-id-type="pmid">26414243</pub-id></mixed-citation></ref><ref id="pone.0180726.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Matsushita</surname><given-names>T</given-names></name>, <name><surname>Hamaguchi</surname><given-names>Y</given-names></name>, <name><surname>Hasegawa</surname><given-names>M</given-names></name>, <name><surname>Takehara</surname><given-names>K</given-names></name>, <name><surname>Fujimoto</surname><given-names>M</given-names></name>. <article-title>Decreased levels of regulatory B cells in patients with systemic sclerosis: association with autoantibody production and disease activity</article-title>. <source>Rheumatology (Oxford)</source>. <year>2016</year>;<volume>55</volume>:<fpage>263</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26350483</pub-id></mixed-citation></ref><ref id="pone.0180726.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Chen</surname><given-names>M</given-names></name>, <name><surname>Zhang</surname><given-names>L</given-names></name>, <name><surname>Ren</surname><given-names>Y</given-names></name>, <name><surname>Zhang</surname><given-names>K</given-names></name>, <name><surname>Yang</surname><given-names>Y</given-names></name>, <name><surname>Fang</surname><given-names>Y</given-names></name>, <etal>et al</etal>
<article-title>Defective Function of CD24(+)CD38(+) Regulatory B Cells in Ankylosing Spondylitis</article-title>. <source>DNA Cell Biol</source>. <year>2016</year>;<volume>35</volume>:<fpage>88</fpage>&#x02013;<lpage>95</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1089/dna.2015.3046">10.1089/dna.2015.3046</ext-link></comment>
<pub-id pub-id-type="pmid">26556289</pub-id></mixed-citation></ref><ref id="pone.0180726.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>van der Linden</surname><given-names>S</given-names></name>, <name><surname>Valkenburg</surname><given-names>HA</given-names></name>, <name><surname>Cats</surname><given-names>A</given-names></name>. <article-title>Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria</article-title>. <source>Arthritis Rheum</source>
<year>1984</year>;<volume>27</volume>:<fpage>361</fpage>&#x02013;<lpage>8</lpage>. <pub-id pub-id-type="pmid">6231933</pub-id></mixed-citation></ref><ref id="pone.0180726.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Machado</surname><given-names>P</given-names></name>, <name><surname>Landew&#x000e9;</surname><given-names>R</given-names></name>, <name><surname>Lie</surname><given-names>E</given-names></name>, <name><surname>Kvien</surname><given-names>TK</given-names></name>, <name><surname>Braun</surname><given-names>J</given-names></name>, <name><surname>Baker</surname><given-names>D</given-names></name>, <name><surname>van der Heijde</surname><given-names>D</given-names></name>; <collab>Assessment of SpondyloArthritis international Society</collab>. <article-title>Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores</article-title>. <source>Ann Rheum Dis</source>. <year>2011</year>;<volume>70</volume>:<fpage>47</fpage>&#x02013;<lpage>53</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/ard.2010.138594">10.1136/ard.2010.138594</ext-link></comment>
<pub-id pub-id-type="pmid">21068095</pub-id></mixed-citation></ref><ref id="pone.0180726.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Turina</surname><given-names>MC</given-names></name>, <name><surname>Yeremenko</surname><given-names>N</given-names></name>, <name><surname>Paramarta</surname><given-names>JE</given-names></name>, <name><surname>De Rycke</surname><given-names>L</given-names></name>, <name><surname>Baeten</surname><given-names>D</given-names></name>. <article-title>Calprotectin (S100A8/9) as serum biomarker for clinical response in proof-of-concept trials in axial and peripheral spondyloarthritis</article-title>. <source>Arthritis Res Ther</source>. <year>2014</year>;<volume>16</volume>:<fpage>413</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1186/s13075-014-0413-4">10.1186/s13075-014-0413-4</ext-link></comment>
<pub-id pub-id-type="pmid">25135077</pub-id></mixed-citation></ref><ref id="pone.0180726.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Cypers</surname><given-names>H</given-names></name>, <name><surname>Varkas</surname><given-names>G</given-names></name>, <name><surname>Beeckman</surname><given-names>S</given-names></name>, <name><surname>Debusschere</surname><given-names>K</given-names></name>, <name><surname>Vogl</surname><given-names>T</given-names></name>, <name><surname>Roth</surname><given-names>J</given-names></name>, <etal>et al</etal>
<article-title>Elevated calprotectin levels reveal bowel inflammation in spondyloarthritis</article-title>. <source>Ann Rheum Dis</source>. <year>2016</year>;<volume>75</volume>:<fpage>1357</fpage>&#x02013;<lpage>62</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/annrheumdis-2015-208025">10.1136/annrheumdis-2015-208025</ext-link></comment>
<pub-id pub-id-type="pmid">26698844</pub-id></mixed-citation></ref><ref id="pone.0180726.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Gill</surname><given-names>T</given-names></name>, <name><surname>Asquith</surname><given-names>M</given-names></name>, <name><surname>Rosenbaum</surname><given-names>JT</given-names></name>, <name><surname>Colbert</surname><given-names>RA</given-names></name>. <article-title>The intestinal microbiome in spondyloarthritis</article-title>. <source>Curr Opin Rheumatol</source>. <year>2015</year>;<volume>27</volume>:<fpage>319</fpage>&#x02013;<lpage>25</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1097/BOR.0000000000000187">10.1097/BOR.0000000000000187</ext-link></comment>
<pub-id pub-id-type="pmid">26002022</pub-id></mixed-citation></ref><ref id="pone.0180726.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Rosenbaum</surname><given-names>JT</given-names></name>, <name><surname>Davey</surname><given-names>MP</given-names></name>. <article-title>Time for a gut check: evidence for the hypothesis that HLA-B27 predisposes to ankylosing spondylitis by altering the microbiome</article-title>. <source>Arthritis Rheum</source>. <year>2011</year>;<volume>63</volume>:<fpage>3195</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/art.30558">10.1002/art.30558</ext-link></comment>
<pub-id pub-id-type="pmid">21792826</pub-id></mixed-citation></ref><ref id="pone.0180726.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Mart&#x000ed;nez-Gonz&#x000e1;lez</surname><given-names>O</given-names></name>, <name><surname>Cantero-Hinojosa</surname><given-names>J</given-names></name>, <name><surname>Paule-Sastre</surname><given-names>P</given-names></name>, <name><surname>G&#x000f3;mez-Mag&#x000e1;n</surname><given-names>JC</given-names></name>, <name><surname>Salvatierra-R&#x000ed;os</surname><given-names>D</given-names></name>. <article-title>Intestinal permeability in patients with ankylosing spondylitis and their healthy relatives</article-title>. <source>Br J Rheumatol</source>
<year>1994</year>; <volume>33</volume>:<fpage>644</fpage>&#x02013;<lpage>647</lpage>. <pub-id pub-id-type="pmid">8019793</pub-id></mixed-citation></ref><ref id="pone.0180726.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Mielants</surname><given-names>H</given-names></name>, <name><surname>Veys</surname><given-names>EM</given-names></name>, <name><surname>Goemaere</surname><given-names>S</given-names></name>, <name><surname>Goethals</surname><given-names>K</given-names></name>, <name><surname>Cuvelier</surname><given-names>C</given-names></name>, <name><surname>de Vos</surname><given-names>M</given-names></name>. <article-title>Gut inflammation in the spondyloarthropathies: clinical, radiologic, biologic and genetic features in relation to the type of histology. A prospective study</article-title>. <source>J Rheumatol</source>
<year>1991</year>; <volume>18</volume>:<fpage>1542</fpage>&#x02013;<lpage>1551</lpage>. <pub-id pub-id-type="pmid">1765980</pub-id></mixed-citation></ref><ref id="pone.0180726.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Demetter</surname><given-names>P</given-names></name>, <name><surname>Van Huysse</surname><given-names>JA</given-names></name>, <name><surname>De Keyser</surname><given-names>F</given-names></name>, <name><surname>Van Damme</surname><given-names>N</given-names></name>, <name><surname>Verbruggen</surname><given-names>G</given-names></name>, <name><surname>Mielants</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Increase in lymphoid follicles and leukocyte adhesion molecules emphasizes a role for the gut in spondyloarthropathy pathogenesis</article-title>. <source>J Pathol</source>
<year>2002</year>; <volume>198</volume>: <fpage>517</fpage>&#x02013;<lpage>522</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1002/path.1235">10.1002/path.1235</ext-link></comment>
<pub-id pub-id-type="pmid">12434422</pub-id></mixed-citation></ref><ref id="pone.0180726.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Hindryckx</surname><given-names>P</given-names></name>, <name><surname>Laukens</surname><given-names>D</given-names></name>, <name><surname>Serry</surname><given-names>G</given-names></name>, <name><surname>Van Praet</surname><given-names>L</given-names></name>, <name><surname>Cuvelier</surname><given-names>C</given-names></name>, <name><surname>Mielants</surname><given-names>H</given-names></name>, <etal>et al</etal>
<article-title>Subclinical gut inflammation in spondyloarthritis is associated with a pro-angiogenic intestinal mucosal phenotype</article-title>. <source>Ann Rheum Dis</source>. <year>2011</year>; <volume>70</volume>:<fpage>2044</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/ard.2010.149229">10.1136/ard.2010.149229</ext-link></comment>
<pub-id pub-id-type="pmid">21873332</pub-id></mixed-citation></ref><ref id="pone.0180726.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Rigoni</surname><given-names>R</given-names></name>, <name><surname>Fontana</surname><given-names>E</given-names></name>, <name><surname>Guglielmetti</surname><given-names>S</given-names></name>, <name><surname>Fosso</surname><given-names>B</given-names></name>, <name><surname>D'Erchia</surname><given-names>AM</given-names></name>, <name><surname>Maina</surname><given-names>V</given-names></name>, <etal>et al</etal>
<article-title>Intestinal microbiota sustains inflammation and autoimmunity induced by hypomorphic RAG defects</article-title>. <source>J Exp Med</source>. <year>2016</year>;<volume>213</volume>:<fpage>355</fpage>&#x02013;<lpage>75</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1084/jem.20151116">10.1084/jem.20151116</ext-link></comment>
<pub-id pub-id-type="pmid">26926994</pub-id></mixed-citation></ref><ref id="pone.0180726.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Ochoa-Rep&#x000e1;raz</surname><given-names>J</given-names></name>, <name><surname>Mielcarz</surname><given-names>DW</given-names></name>, <name><surname>Haque-Begum</surname><given-names>S</given-names></name>, <name><surname>Kasper</surname><given-names>LH</given-names></name>. <article-title>Induction of a regulatory B cell population in experimental allergic encephalomyelitis by alteration of the gut commensal microflora</article-title>. <source>Gut Microbes</source>
<year>2010</year>;<volume>1</volume>:<fpage>103</fpage>&#x02013;<lpage>108</lpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.4161/gmic.1.2.11515">10.4161/gmic.1.2.11515</ext-link></comment>
<pub-id pub-id-type="pmid">21326918</pub-id></mixed-citation></ref><ref id="pone.0180726.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Rosser</surname><given-names>EC</given-names></name>, <name><surname>Oleinika</surname><given-names>K</given-names></name>, <name><surname>Tonon</surname><given-names>S</given-names></name>, <name><surname>Doyle</surname><given-names>R</given-names></name>, <name><surname>Bosma</surname><given-names>A</given-names></name>, <name><surname>Carter</surname><given-names>NA</given-names></name>, <etal>et al</etal>
<article-title>Regulatory B cells are induced by gut microbiota-driven interleukin-1&#x003b2; and interleukin-6 production</article-title>. <source>Nat Med</source>. <year>2014</year>;<volume>20</volume>:<fpage>1334</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.3680">10.1038/nm.3680</ext-link></comment>
<pub-id pub-id-type="pmid">25326801</pub-id></mixed-citation></ref><ref id="pone.0180726.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Schroeder</surname><given-names>BO</given-names></name>, <name><surname>B&#x000e4;ckhed</surname><given-names>F</given-names></name>. <article-title>Signals from the gut microbiota to distant organs in physiology and disease</article-title>. <source>Nat Med</source>. <year>2016</year>;<volume>22</volume>:<fpage>1079</fpage>&#x02013;<lpage>1089</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038/nm.4185">10.1038/nm.4185</ext-link></comment>
<pub-id pub-id-type="pmid">27711063</pub-id></mixed-citation></ref><ref id="pone.0180726.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Fonseca-Camarillo</surname><given-names>G</given-names></name>, <name><surname>Furuzawa-Carballeda</surname><given-names>J</given-names></name>, <name><surname>Yamamoto-Furusho</surname><given-names>JK</given-names></name>. <article-title>Interleukin 35 (IL-35) and IL-37: Intestinal and peripheral expression by T and B regulatory cells in patients with Inflammatory Bowel Disease</article-title>. <source>Cytokine</source>. <year>2015</year>;<volume>75</volume>:<fpage>389</fpage>&#x02013;<lpage>402</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.cyto.2015.04.009">10.1016/j.cyto.2015.04.009</ext-link></comment>
<pub-id pub-id-type="pmid">26141420</pub-id></mixed-citation></ref><ref id="pone.0180726.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Jones-Hall</surname><given-names>YL</given-names></name>, <name><surname>Kozik</surname><given-names>A</given-names></name>, <name><surname>Nakatsu</surname><given-names>C</given-names></name>. <article-title>Ablation of tumor necrosis factor is associated with decreased inflammation and alterations of the microbiota in a mouse model of inflammatory bowel disease</article-title>. <source>PLoS One</source>. <year>2015</year>
<month>3</month>
<day>16</day>;<volume>10</volume>(<issue>3</issue>):<fpage>e0119441</fpage>
<comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1371/journal.pone.0119441">10.1371/journal.pone.0119441</ext-link></comment>
<pub-id pub-id-type="pmid">25775453</pub-id></mixed-citation></ref><ref id="pone.0180726.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Jones-Hall</surname><given-names>YL</given-names></name>, <name><surname>Nakatsu</surname><given-names>CH</given-names></name>. <source>Gut Microbes</source>. <article-title>The Intersection of TNF, IBD and the Microbiome</article-title>. <year>2016</year>;<volume>7</volume>:<fpage>58</fpage>&#x02013;<lpage>62</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1080/19490976.2015.1121364">10.1080/19490976.2015.1121364</ext-link></comment>
<pub-id pub-id-type="pmid">26939853</pub-id></mixed-citation></ref><ref id="pone.0180726.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Gibson</surname><given-names>PR</given-names></name> (<year>2004</year>) <article-title>Increased gut permeability in Crohn&#x02019;s disease: is TNF the link?</article-title>
<source>Gut</source>
<volume>53</volume>:<fpage>1724</fpage>&#x02013;<lpage>1725</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1136/gut.2004.047092">10.1136/gut.2004.047092</ext-link></comment>
<pub-id pub-id-type="pmid">15542502</pub-id></mixed-citation></ref><ref id="pone.0180726.ref033"><label>33</label><mixed-citation publication-type="journal"><name><surname>Watson</surname><given-names>AJ</given-names></name>, <name><surname>Hughes</surname><given-names>KR</given-names></name>. <article-title>TNF-&#x003b1;-induced intestinal epithelial cell shedding: implications for intestinal barrier function</article-title>. <source>Ann N Y Acad Sci</source>. <year>2012</year>;<volume>1258</volume>:<fpage>1</fpage>&#x02013;<lpage>8</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1749-6632.2012.06523.x">10.1111/j.1749-6632.2012.06523.x</ext-link></comment>
<pub-id pub-id-type="pmid">22731709</pub-id></mixed-citation></ref><ref id="pone.0180726.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Suenaert</surname><given-names>P</given-names></name>, <name><surname>Bulteel</surname><given-names>V</given-names></name>, <name><surname>Lemmens</surname><given-names>L</given-names></name>, <name><surname>Noman</surname><given-names>M</given-names></name>, <name><surname>Geypens</surname><given-names>B</given-names></name>, <name><surname>Van Assche</surname><given-names>G</given-names></name>, <etal>et al</etal>
<article-title>Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease</article-title>. <source>Am J Gastroenterol</source>. <year>2002</year>;<volume>97</volume>:<fpage>2000</fpage>&#x02013;<lpage>4</lpage>. <comment>doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1111/j.1572-0241.2002.05914.x">10.1111/j.1572-0241.2002.05914.x</ext-link></comment>
<pub-id pub-id-type="pmid">12190167</pub-id></mixed-citation></ref></ref-list></back></article>